The role of hydrogen sulfide in doxorubicin-induced drug resistance in hepatocellular carcinoma cells

by

Eric Stokes

A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science (MSc) in Biology

The Faculty of Graduate Studies
Laurentian University
Sudbury, Ontario, Canada

© Eric Stokes, 2018
Title of Thesis
Titre de la thèse
The role of hydrogen sulfide in doxorubicin-induced drug resistance in hepatocellular carcinoma cells

Name of Candidate
Nom du candidat
Stokes, Eric

Degree
Diplôme
Master of Science

Department/Program
Département/Programme
MSc Biology

Date of Defence
Date de la soutenance
September 17, 2018

APPROVED/APPROUVÉ

Thesis Examiners/Examinateurs de thèse:

Dr. Guangdon Yang
(Supervisor/Directeur de thèse)

Dr. Eric Gauthier
(Committee member/Membre du comité)

Dr. Jeffrey Gagnon
(Committee member/Membre du comité)

Dr. Rui Wang
(Approved for the Faculty of Graduate Studies
(Supervisor/Directeur de thèse)

Dr. David Lesbarrères
(Monsieur David Lesbarrères)

Dr. Wenbin Liang
(Approved by the Faculty of Graduate Studies
(External Examiner/Examinateur externe)

Dean, Faculty of Graduate Studies
Doyen, Faculté des études supérieures

ACCESSIBILITY CLAUSE AND PERMISSION TO USE

I, Eric Stokes, hereby grant to Laurentian University and/or its agents the non-exclusive license to archive and make accessible my thesis, dissertation, or project report in whole or in part in all forms of media, now or for the duration of my copyright ownership. I retain all other ownership rights to the copyright of the thesis, dissertation or project report. I also reserve the right to use in future works (such as articles or books) all or part of this thesis, dissertation, or project report. I further agree that permission for copying of this thesis in any manner, in whole or in part, for scholarly purposes may be granted by the professor or professors who supervised my thesis work or, in their absence, by the Head of the Department in which my thesis work was done. It is understood that any copying or publication or use of this thesis or parts thereof for financial gain shall not be allowed without my written permission. It is also understood that this copy is being made available in this form by the authority of the copyright owner solely for the purpose of private study and research and may not be copied or reproduced except as permitted by the copyright laws without written authority from the copyright owner.
Abstract

Doxorubicin is one of the most common chemical agents used in the treatment of cancers. Doxorubicin-treated cancer cells often develop drug resistance due to alterations in the trafficking and metabolism of the drug, which severely limits the drug’s effectiveness. This is seen at especially high rates in human hepatocellular carcinoma (HCC), the most common form of liver cancer. H₂S is an important gasotransmitter and is involved in a variety of cellular functions and pathophysiologic processes. The role of H₂S in drug resistance in cancer cells is still unclear. In this study, by using a human hepatocellular carcinoma cell line (HepG2), we found that NaHS (an H₂S donor) was able to reduce cancer cell viability and colony formation in a doxorubicin dose dependent manner, while H₂S alone did not show any effect. The expression of H₂S-generating enzyme cystathionine gamma-lyase (CSE) but not cystathionine beta-synthase (CBS) was reduced by doxorubicin treatment. In addition, H₂S promoted cellular retention of doxorubicin in HepG2 cells, possibly by suppressing the expression of ABCA1 and ABCG8, two drug efflux proteins. LXRα acts as a transcription factor for ABCA1 and ABCG8, however our findings showed that H₂S had no effect on the protein expression and S-sulfhydration of LXRα, suggesting LXRα is not involved in H₂S-regulated expressions of ABCA1 and ABCG8. In comparison with the parental cells, CSE expression was also reduced in doxorubicin-resistant cells. Exogenously applied NaHS reversed the drug resistance in doxorubicin-resistant cells. In conclusion, our study provides a novel solution for reversing drug resistance by targeting H₂S signaling.

Key words: H₂S, Cystathionine gamma-lyase, human hepatocellular carcinoma, doxorubicin, drug resistance
Abbreviations:

3MST: 3-mercaptopyruvate sulfurtransferase
ABC: ATP-binding cassette
CAT: Cysteine aminotransferase
CBS: Cystathionine β-synthase
CSE: Cystathionine γ-lyase
D.R: Doxorubicin drug resistant
EDRF: Endothelial derived growth factor
GST: glutathione-S-transferase
HAIC: Hepatic artery-infusion chemotherapy
HCC: Primary Hepatocellular Carcinoma
LPS: Lipopolysaccharide
LXR: Liver X receptors
MDR: Multi-drug resistance
PAG: DL-propargylglycine
ROS: Reactive oxygen species
SLC: solute carrier
VEGF: vascular endothelial growth factor
WT: Wild-type
Acknowledgments:

I would like to thank my supervisor Dr. Guangdong Yang, for his expertise, commitment to research, and work ethic that he exemplified throughout my graduate experience here at Laurentian University. I would like to also thank my committee members, Drs. Eric Gauthier, Jeffrey Gagnon, and Rui Wang, for providing thoughtful recommendations and insight into the planning and execution of my research goals.

Special thanks to all members of the Cardiovascular and Metabolic Research Unit, particularly Drs Qiuhui Cao, Ming Fu, and Tian Shuang for their technical support, experimental assistance, and troubleshooting suggestions.

The support of my friends and family has been instrumental in the successful completion of this program, and I would like to thank all those who have lent a helping hand through these past two years.
**Table of Contents**

Abstract .......................................................................................................................................... iii

Acknowledgments: ......................................................................................................................... v

List of Figures ................................................................................................................................ ix

1. Introduction ................................................................................................................................. 1
   1.1 Gasotransmitters ................................................................................................................... 1
   1.2. H$_2$S in mammalian physiology ............................................................................................ 2
   1.3 H$_2$S in pathophysiology ........................................................................................................ 4
   1.4 H$_2$S post-translational modifications of protein by S-sulfhydration ..................................... 9
   1.5 Primary hepatocellular carcinoma (HCC) .............................................................................. 10
   1.6 Doxorubicin as a model chemotherapeutic agent ............................................................... 13
   1.7 Multi-drug resistance (MDR) ............................................................................................. 15
   1.8 H$_2$S as a putative regulator of MDR ................................................................................... 19

2. Methods..................................................................................................................................... 20
   2.1. Cell culture ......................................................................................................................... 20
   2.2. Establishment of a doxorubicin-resistant HepG2 cell line ................................................ 21
   2.3. Cell viability assay ............................................................................................................. 21
   2.4. Clonogenic assay ................................................................................................................. 22
   2.5. Western blotting ................................................................................................................... 22
   2.6. Real-time PCR .................................................................................................................... 23
   2.7. Measurement of H$_2$S production rate .............................................................................. 23
   2.8. H$_2$S direct interaction ....................................................................................................... 24
   2.9. Doxorubicin efflux and influx assay .................................................................................... 24
2.10. S-sulphydration assay ................................................................. 25
2.11. Statistical Analysis ................................................................. 25

3. Results .......................................................................................... 26
3.1 The effects of doxorubicin and H₂S treatment on HepG2 cell survival ................. 26
3.2 H₂S and doxorubicin-induced changes in the clonogenic formation of HepG2 cells........ 28
3.3 The effects of doxorubicin on H₂S-generating enzymes in HepG2 cells ..................... 30
3.4. H₂S modulates doxorubicin trafficking in HepG2 cells .............................................. 32
3.5 Effects of doxorubicin and H₂S on the expression of ABC transport proteins in HepG2
   cells. ........................................................................................................ 34
3.6 The effect of doxorubicin and H₂S on LXRα expression and S-sulphydration .............. 35
3.7 Doxorubicin and H₂S regulate GST and SLC22A1 expression in HepG2 cells ............ 36
3.8. Characterization of doxorubicin drug resistance in HepG2 cells ................................. 38

4. Discussion ......................................................................................... 40

5. Conclusions and future studies ....................................................................... 48

6. References .......................................................................................... 50
List of Tables

Table 1. Classes of chemotherapeutic agents based on mode of activity (adapted from (37))
List of Figures

Figure 1. Mammalian endogenous generation of H₂S through reverse trans-sulfuration............ 3

Figure 2. The inhibitory and proliferative signaling properties of H₂S.....................................8

Figure 3. Cytotoxic signaling properties of doxorubicin (adapted from ((43)))......................14

Figure 4. H₂S enhances doxorubicin-induced cytotoxicity in HepG2 cells..............................27

Figure 5. H₂S sensitizes HepG2 cells to colony disruption by doxorubicin treatment..............29

Figure 6. Doxorubicin attenuates H₂S production in HepG2 cells.........................................31

Figure 7. H₂S promotes cellular retention of doxorubicin in HepG2 cells...............................33

Figure 8. H₂S reverses doxorubicin-induced ABCA1 and ABCG8 expression .......................34

Figure 9. The possible mediation of LXRα/β transcription factors in H₂S-regulated ABC transport proteins .........................................................................................................................35

Figure 10. Co-treatment of doxorubicin and H₂S increases GST and SLC22A1 expression in HepG2 cells........................................................................................................................................37

Figure 11. Reduced H₂S signaling in doxorubicin-resistant HepG2 cells...............................39
1. Introduction

1.1 Gasotransmitters

In 1980, Drs. Furchgott and Zawadzki described the ability of an unknown factor, released by endothelial cells, to induce the relaxation of smooth muscle cells. They termed this molecule an endothelial derived relaxing factor (EDRF), and in 1987, it was discovered to be the gas molecule nitrous oxide. (1). Their research was awarded the Nobel Prize in 1998 alongside Drs. Ignarro and Murad, sparking the interest in the potential for other endogenously produced gaseous molecules to have similar signalling properties. Since that time, both carbon monoxide (CO) and most recently, hydrogen sulfide (H₂S) have been implicated as physiologically relevant molecules in mammalian physiology. In recognition of these gaseous signalling molecules, Dr. Wang coined and defined the term “gasotransmitters”. In order to be recognized as a member of the gasotransmitter group, a molecule needs to meet the 6 criteria outlined below (adapted from (2));

1. They are small molecules of gas.

2. They are freely permeable to the cell membrane. As such, their intracellular and intercellular movements do not exclusively rely on cognate membrane receptors or transport proteins.

3. They are endogenously generated in mammalian cells with specific substrates and enzymes; more than the products of metabolism, their production is regulated to fulfill signaling messenger functions.

4. They have well-defined, specific functions at physiologically relevant concentrations.
5. Functions of endogenous gases can be mimicked by their exogenously applied counterparts.

6. They are involved in signal transduction and have specific cellular and molecular targets.

1.2. H$_2$S in mammalian physiology

H$_2$S has a molecular weight of 34.1 g/mol and is a flammable gas with no colour. It is most commonly associated with its distinct “rotten egg” smell. Initial H$_2$S research focused mostly on its cytotoxic effects, as well as its potential as a major workplace safety concern in the oil industry (3). At the time of its discovery, endogenous H$_2$S production in brain tissues was widely considered to be nothing more than metabolic waste (4). It wasn’t until the discovery of nitric oxide as an important signalling molecule researchers began to look at other endogenously produced gaseous molecules. Since then, the endogenous production of H$_2$S has been well described, and is facilitated by three major enzymes: cystathionine $\beta$-synthase (CBS), cystathionine $\gamma$-lyase (CSE), and 3-mercaptoppyruvate sulfurtransferase (3MST) in conjugation with cysteine aminotransferase (CAT). These enzymes catalyze the conversion of L-cysteine to H$_2$S with pyridoxal 5’ phosphate (vitamin B6) as a cofactor (Fig 1.). Given the importance of L-cysteine in the production of H$_2$S, the regulation of appropriate circulating cysteine is critical for maintaining H$_2$S homeostasis. The production of cysteine in mammalian tissues is performed through the reverse transsulfuration pathway and uses the H$_2$S generating enzymes CSE and CBS to convert homocysteine to cystathionine, and then finally to cysteine (Fig 1.).
Figure 1. Mammalian endogenous generation of H$_2$S through reverse transsulfuration

H$_2$S is capable of inducing cellular changes through a process known as protein S-sulfhydration. This involves the conversion of thiol –SH groups in the cysteine residues of target proteins, to hydropersulfide –SSH groups, changing both the structure and functionality of these proteins (5). In doing so, H$_2$S is capable of carrying out a huge number of signalling roles in most of the major organ systems. H$_2$S-mediated S-sulfhydration of the NF-κB p65 subunit has been shown to increase NF-κB transcriptional activity, thus providing increased protection from cellular apoptosis (6). In human endothelial and fibroblast cells, S-sulfhydration of the mitogen-activated protein kinase (MEK1) results in activation of poly (ADP-ribose) polymerase 1 (PARP1), an important enzyme associated with DNA repair mechanisms (7). In response to
injury in a mouse model, increased levels of S-sulfhydration of the ATP synthase alpha subunit was associated with increased ATP synthase activity. This suggests a role S-sulfhydration in regulating and maintaining necessary energy production during times of cellular stress (8).

The first described role of H$_2$S as a gasotransmitter was it’s signalling properties within the nervous system. In the central nervous system, H$_2$S is capable of enhancing the post-synaptic potentials of excitatory neurotransmission through increasing the sensitivity of NMDA receptors to glutamate signalling (9). H$_2$S has also been shown to enhance the production of GABA receptors, leading to inhibitory neurotransmission in the central nervous system (10). In the cardiovascular system, exogenous H$_2$S has been shown to reduce both heart rate and contractility through the opening of K$_{ATP}$ channels, causing subsequent potassium efflux and hyperpolarization of myocytes (11, 12). The effect of H$_2$S on K$_{ATP}$ channels has also been implicated in the regulation of vascular smooth muscles, inducing the relaxation of blood vessels and thus regulating systemic blood flow (13). Of all the organ systems, H$_2$S production in the liver occurs at exceptionally high levels, ranging from 30-90% higher than in vascular tissues. Because of this, some researchers have suggested that the liver is one of the major sites of H$_2$S production in the body, and thus makes it a key target organ for studying the signalling roles of H$_2$S (14). Currently, the main role of H$_2$S in the liver is associated with the regulation of hepatic circulation through targeting of K$_{ATP}$ channels. In doing so, H$_2$S has been shown to induce vasodilation of the hepatic artery, thus ensuring adequate hepatic clearance (15).

1.3 H$_2$S in pathophysiology

Given the importance of H$_2$S production in mammalian physiology, researchers have become interested in describing the role of H$_2$S in new and unique cellular signaling
mechanisms, specifically in the onset and regulation of disease. Today, our understanding of H2S in pathophysiology continues to open up new possibilities for H2S as a clinically relevant tool.

Within the immune system, evidence has suggested both a pro and anti-inflammatory role of H2S. Given the importance of inflammation in the onset of many pathological conditions, as well as the danger that unregulated inflammation itself can pose, the role of H2S in inflammatory signalling should not be understated. The pro-inflammatory effect of H2S has been shown in lipopolysaccharide (LPS)-induced inflammation in mouse models, where plasma H2S levels were significantly increased. Additionally, administration of the H2S donor sodium hydrosulfide (NaHS) increased histological signs of inflammatory damage in lung and liver tissues (16). Elevated H2S levels were also shown to be associated with induced systemic inflammation, while the use of the CSE inhibitor DL-propargylglycine (PAG) significantly reduced the inflammatory response, and NaHS treatment further aggravated it (17). Conversely, as an anti-inflammatory molecule, one study showed the ability for inhaled H2S to restrict LPS induced systemic inflammation, again highlighting the sometimes conflicting regulatory activity of H2S (18). H2S donor treatment was shown to restrict the ability for leukocyte attachment to mesenteric endothelium cells, a key step in the initiation of inflammation. Similarly, H2S treatment was shown to limit induced paw edema in animal models, while inhibition of H2S production had the opposite effect (19).

Another important function of this gasotransmitter is its ability to regulate apoptosis. In a manner similar to inflammation, the specific role of H2S in apoptosis is conflicted. H2S has been shown to induce apoptosis of human aortic smooth muscle cells (HASMC) (20). Overexpression of the gene encoding CSE, a major H2S-generating enzyme in the vascular system, enhanced endogenous H2S production and induced significant levels of HASMC apoptosis. Furthermore,
CSE inhibition through the use of CSE-specific short interfering (si)-RNA exaggerated these effects, suggesting the importance of endogenously produced H₂S in sensitizing these cells to pro-apoptotic signaling events. It was shown that exogenous H₂S increased protein expression of p21Cip and decreased protein expression of cyclin D1, further pointing to its role as a pro-apoptotic signaling molecule (20). Building upon these initial findings, researchers next looked at the role of H₂S in regulating apoptotic events in cancerous cell lines. Lee et. al. investigated the effects of H₂S exposure on both breast (MCF7) and liver (HepG2) cancer cell lines (21). Through the use of the H₂S donor NaHS, continuous H₂S treatment over a 5-day period resulted in a significant decrease in cell viability. This was also shown to be specific to only cancer cell line variants, with the same treatment having no effect on corresponding wild-type cells. The researchers proposed that this apparent anti-cancer effect was caused by H₂S-induced uncoupling of mitochondrial electron transport chain. As a result, these cells become more heavily reliant on glycolytic ATP production, with lactic acid produced as a by-product. Because of the high metabolic demands of cancerous cells relative to wild-type cells, these effects became exaggerated in the cancerous lines. The increased lactic acid production and therefore decreased intracellular pH led to damaging cytosolic conditions and ultimately, cancer cell death (21).

Similar inhibitory effects were also seen in cancerous gastric cell lines. Following 24-hour H₂S treatments at concentrations ranging from 200-800 μM, gastric cancer (SGC7901) cells exhibited significant levels of apoptosis in a dose-dependent manner (22). In the same study, H₂S was also shown to effectively inhibit both gastric cancer invasion and migration, reducing the ability of the cancerous cells to metastasise. It was proposed that the H₂S-induced the up regulation of Bax, Cytochrome C and Caspase 3, important factors in the intrinsic apoptotic pathway, was responsible for these effects (22).
However, equally convincing data has been collected suggesting that instead of stimulating cell apoptosis, H₂S actually increases cell proliferation and metabolic activity. Szabo \textit{et al}. presented these findings, using a colon cancer cell line, HCT116 (23). Szabo and his colleagues found that CBS knockdown resulted in a significant decrease in H₂S production, implicating CBS as the major H₂S-generating enzyme in these cells. CBS-knockdown also resulted in an approximately 50% decrease in the levels of HCT 116 cell proliferation, while also resulting in down regulation of cellular respiration and ATP synthesis. Szabo et al. also treated both a non-cancerous colon cell line (NCM356) and the HCT 116 cells with aminooxyacetic acid (AOAA), a CBS inhibitor, and found that the resultant CBS inhibition had anti-proliferative effects in the HCT116, but not the NCM356 cells. Conversely, CBS overexpression in the NCM356 cells actually increased cell proliferation, highlighting how, even within the same tissue type, pathological cellular conditions can be affected by the signalling role of H₂S. To explain these effects, the researchers pointed to the ability of H₂S to promote cellular bioenergetic processes such as glycolytic and electron transport chain activity, as well as its stimulatory effects on cell survival mechanisms, such as the Akt-pathway (23). Other studies have pointed to the ability of H₂S to scavenge reactive oxygen species (ROS) and to restrict tumor suppressing gene P53 expression to explain its stimulatory effects (24). A summary of some of the current knowledge on the inhibitory (Fig 2A) and stimulatory (Fig 2B) effects of H₂S on cell growth and activity is provided below.
Figure 2. Inhibitory and proliferative signaling properties of H₂S
While it is clear that H₂S plays an important role in the regulation of inflammation and apoptosis, it does so to a wide degree of variability. As a result, it can exhibit sometimes opposing functions depending on factors such as the type and concentration of H₂S donor used, the modification of either endogenous or application of exogenous H₂S sources, as well as the tissue type being studied. What is clear however, is the ability for H₂S to play a key role in major disease processes. This offers the potential for new discoveries, especially in tissues where H₂S production is significant, but its exact role is still poorly understood, the liver being a prime example of such conditions.

1.4 H₂S post-translational modifications of protein by S-sulfhydration

S-sulfhydration, or S-persulfidation, is a newly discovered protein post-translational modification by yielding a hydopersulfide moiety (–SSH) in the active cysteine residues. By changing local conformation and the final activity of target proteins, S-sulfhydration is believed to mediate most of cellular responses initiated by H₂S. Since the first finding of S-sulfhydration on proteins was described in 2009 (5), many proteins have been reported to be S-sulfhydrated and involved in the physiological and pathological functions of H₂S. H₂S acts as an endothelium-derived relaxing factor (EDRF) through S-sulfhydration of potassium channel proteins (25). S-sulfhydration of Keap1 provides protection against cellular senescence via the regulation of Nrf2.

1 (This section has been published as part of a review paper titled “H₂S-mediated protein S-sulfhydration: a prediction for its formation and regulation in Molecules. Vol. 2017, doi 10.3390/molecules22081334).
activity (26). Recently, it was found that S-sulfhydration of MEK1 is associated with repairing damaged DNA inside the cell (7). eNOS S-sulfhydration regulates eNOS activity through the regulation of eNOS dimerization (27). In addition, abnormal protein S-sulfhydration have been found to be involved in multiple sclerosis (28), antioxidants (29), neuroprotection (30), and endoplasmic reticulum stress response (31) by altering enzymatic activity, protein localization, protein–protein interactions, and protein stability.

Despite the importance of protein S-sulfhydration in diverse cellular functions and pathophysiological responses, the regulatory mechanism of protein S-sulfhydration are largely unclear. The interaction or competition between cysteine S-sulfhydration and other protein post-translational modifications (Sulfenylation, S-nitrosylation, and glutathionylation, etc) in the same protein need to be determined. Due to the instability and transient nature of s-sulfhydration moieties, the development of better detection technology and methodologies for protein S-sulfhydration is required for an improved understanding of its formation and wide biological implications.

1.5 Primary hepatocellular carcinoma (HCC)

Primary HCC is the most common form of primary liver cancer, making up 70-85% of all liver cancer diagnoses. HCC has the second highest mortality rate of all cancers in men, and the sixth highest in women, making it one of the most significant cancer forms worldwide (32). While HCC variants exist, all of them are associated with deregulated hepatocyte cell growth, and in some cases, metastasis (33). HCC etiology in developing countries is most commonly associated with viral hepatitis B/C infection, while in western countries has been linked to alcoholism and obesity (32).
The prognosis associated with HCC is quite poor and the overall survival rate of patients with HCC remains very low. The most successful treatment option available for individuals is complete liver transplantation, with a 5-year survival rate of 61%. Similarly, surgical removal of cancerous tissues has also shown to be an effective treatment strategy, with 5-year survival rates upwards of 50%. Despite their promise, these treatments are severely restricted by long wait periods, and the numerous co-morbidities associated with HCC complicate the procedures, including diabetes, kidney, and cardiovascular diseases (34). Other treatment forms include chemotherapeutic and radiotherapy, as well as selective blockage of blood supply to the tumor. These treatments are, again, limited in their usefulness based on the size and location of the tumor (35).

Chemotherapeutics are some of the most widely used treatment tools for most forms of cancer, including HCC. These chemicals are applied both systemically in a non tumor-specific manner, or locally targeted to the cancerous tissues. While the hepatic artery supplies the liver with 25% of total blood flow, the remainder coming from the portal vein, studies have shown that HCC tumors receive close to 90% of its blood supply from the hepatic artery (36). As such, treatments can be facilitated to supply chemotherapeutic agents directly to target HCC tissues through the hepatic artery, in a method known as hepatic artery-infusion chemotherapy (HAIC) (36, 37). Modern chemotherapeutics can be organized into the following classes as described in table 1.
Table 1. Classes of chemotherapeutic agents based on mode of activity (adapted from (38)).

<table>
<thead>
<tr>
<th>Class</th>
<th>Example</th>
<th>Applications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antimetabolites</td>
<td>5-fluorouracil</td>
<td>Hepatic artery infusion chemotherapy, HCC treatment</td>
</tr>
<tr>
<td>Biological Agents</td>
<td>Bevacizumab</td>
<td>Colorectal metastases associated with HCC</td>
</tr>
<tr>
<td>Multi-kinase Inhibitors</td>
<td>Sorafenib</td>
<td>Systemic treatment of HCC and renal cell carcinoma (RCC)</td>
</tr>
<tr>
<td>Platinum salts</td>
<td>Cisplatin</td>
<td>HCC and associated metastases treatment</td>
</tr>
<tr>
<td>Antineoplastic Antibiotics</td>
<td>Doxorubicin</td>
<td>HCC and associated metastases treatment</td>
</tr>
</tbody>
</table>
Antimetabolites such as 5-fluorouracil work to inhibit the production of essential biomolecules such as nucleotides. Biological agents instead use the patient's own immune system to directly target tumors or modulate hormone levels necessary for tumor establishment and growth, and are specifically useful in the treatment of breast and prostate cancers. Agents such as sorafenib, which fall under the multi-kinase inhibitor class, target the signal transduction pathways associated with protein kinases. Sorafenib specifically blocks the protein kinase receptor for vascular endothelial growth factor (VEGF), which in turn prevents the production of new tumor vasculature, depriving the tumor of oxygen and inducing cell death. Platinum salts work through inducing DNA strand cross linkages which interrupts the DNA replication/repair machinery, leading to apoptosis in the rapidly dividing cancer cells. One of the most well studied and widely used group of chemotherapeutics are the anti-neoplastic antibiotics. First discovered in the *Streptomyces* bacteria as a tool used to inhibit the growth of competitive bacteria, anti-neoplastic antibiotics have clinical usefulness as well (38). Of the antineoplastic antibiotics available, doxorubicin is one of the most well studied and widely used agents, with clinical applications across a wide range of cancers, including HCC (39).

**1.6 Doxorubicin as a model chemotherapeutic agent**

Doxorubicin, trade name as adriamycin, was first employed as an anticancer agent in 1970. Since that time, doxorubicin has become one of the most commonly used treatment tools for the management of cancers of the lung, breast, and liver to name a few (40–42). Doxorubicin carries out its cytotoxic effects as outlined in figure 3.
Figure 3. Cytotoxic signaling properties of doxorubicin (adapted from (43))
Doxorubicin is capable of directly inducing lipid peroxidation, thus damaging elements of the cell membrane and nucleus. While these effects have been shown to be especially damaging in cardiomyocytes, resulting in cardiotoxicity, it is not the primary mechanism in which doxorubicin induces cell death (44). The majority of doxorubicin’s effects come from interruption of DNA replication machinery and generation of ROS. Once inside the cell, doxorubicin is capable of interacting with mitochondrial reductases to produce a doxorubicin semiquinone, which then reduces free oxygen to a superoxide anion. The superoxide anion is then capable of further reacting with DNA, lipids, and proteins, damaging their functionality and inducing cell death (45). Doxorubicin itself can directly enter the nucleus and intercalate with DNA, inducing strand breaks. It can then bind topoisomerase II during the DNA repair process, sequestering it and reducing topoisomerase availability, thus leading to extensive, irreparable DNA damage, and thus cell death (46). While these effects will occur in both the patients healthy and cancerous cells, the direct targeting of DNA replication and repair machinery makes doxorubicin’s cytotoxicity more specific to cancer cells. While it’s clear that the anti-cancer effects of doxorubicin are significant and varied, like the other treatment methods mentioned above, it suffers from several limitations as well. One of the most significant and commonly seen in the treatment of HCC, is a reduced anti-cancer response over extended treatment periods, a condition known as multi-drug resistance (MDR).

1.7 Multi-drug resistance (MDR)

Cellular resistance to normally toxic compounds was first studied in bacteria and by looking at the ability to adapt to certain antibiotic treatments (47). Building upon these findings, researchers discovered similar processes occurring in certain forms of human pathology, specifically in the treatment of cancers. Given the many difficulties associated with the curative
treatment of HCC, patients often only have chemotherapeutic related treatments available to them (48). These treatments can last several months, following a reduction in the responsiveness to the chemotherapeutic agents, a phenomenon termed as multi-drug resistance (MDR) (49).

MDR is a multifactorial issue, and is characterized by changes in the metabolism, intracellular targeting, and transport of the chemotherapeutic agents (50). To study the onset and regulation of these mechanisms, researchers study protein expression levels associated with the cellular management of chemotherapeutics. The majority of research on MDR focuses on drug efflux, specifically through a group of membrane bound proteins called the ATP-binding cassette (ABC) transport proteins. There are 48 ABC transport proteins, which are divided into 7 subgroups (A to G). These proteins are responsible for the transport of a wide variety of hydrophobic compounds such as metal ions, lipids, and sterol based metabolites, etc. (51). These ABC transporters facilitate unidirectional movement based on concentration gradients. The structure of most ABC transporters consists of 6 transmembrane α-helices, in which the transmembrane pore is only accessible from one side of the lipid bilayer (52). The transmembrane domains act as the site of intracellular substrate binding, followed by the binding of ATP to the nucleotide binding domains. ATP hydrolysis catalyzes change of the transporter from the inward to outward facing conformation, followed by extracellular substrate release and ADP dissociation to return the protein back to the inward facing conformation, allowing for another round of transport activity (53). Abnormalities in ABC transporter protein expression and function can lead to a host of different disorders. Polymorphisms of ABCA2, expressed in brain tissues, has been associated with the changes in brain cholesterol transport associated with the onset of Alzheimer’s Disease (54), while ABCB4 mutations can result in a condition known as Progressive familial intrahepatic cholestasis (PFIC), characterized by bile accumulation in
hepatocytes (55). In cancerous cells, overexpression or increased activity levels of these proteins can result in decreased intracellular accumulation of chemotherapeutic agents, which has been implicated as one of the major causes MDR. The role of ABCB1/MDR1 in chemotherapeutic drug resistance has been extensively studied across several cell types ranging from myelogenous leukemia cells to breast cancer cells (56, 57). Other members of the ABC family have also been implicated in poor chemotherapeutic treatment prognosis. In human lung adenocarcinoma (A549) cells, ABCA1 down-regulation increased the cytotoxic activity of the chemotherapeutic agent nitidine (58). ABCG2/BCRP was shown to be highly expressed in a doxorubicin resistant human breast cancer (MCF-7/AdrVp) cell line, implicating it, and possibly other ABCG subgroup members, as major regulators of MDR. The regulation of these proteins is a tightly controlled process which includes a host of different transcription factors, some of which are shared between different members of the ABC group. Liver X receptors (LXRs) are a group of nuclear bound receptors that, through the binding of their ligands, promote the expression of target genes through the formation of a co-factor protein complex. The two subtypes of LXR’s, alpha and beta, are believed to be activated by the same ligands, and differ only in their tissue distribution, with alpha expression occurring mostly in the liver, and beta expression distributed evenly throughout most tissues (59). LXR’s are activated through the presence of sterol based metabolites and have been shown to regulate the expression of certain ABC proteins in order to control cholesterol transport. ABCA1 and ABCG8 are two ABC transport proteins that are induced by LXR alpha/beta to promote excess cholesterol efflux in gut lumen tissue (60). While the role of ABCA1 and ABCG8 in cholesterol homeostasis has been well described, their role in the efflux of chemotherapeutic agents has yet to be studied and could offer new insight into the development of MDR.
The ability for cancerous cells to detoxify chemotherapeutic agents has also been shown to have importance in the onset of MDR (61). The glutathione-S-transferase (GST) group is a large family of enzymes that are capable of catalyzing the conjugation of glutathione to various xenobiotic substrates for the purpose of detoxification (62). Once conjugated to glutathione, the xenobiotic substrates are then transported through the cytoplasm and processed through the mercapturic pathway in the cytosol. Once the resultant mercapturic acids are formed, they are released into circulation and then escape into the urine (63). GST is capable catalyzing the conjugation of glutathione to several different chemotherapeutic agents, removing them from circulation and the intended site of treatment, which is a proposed mechanism for MDR (62).

Elevated GST levels have been studied as a prognostic tool for MDR in human ovarian cancer, with one study identifying 90% of drug resistant tumors as having increased GST levels (64). In Mouse embryo fibroblast cells, GST overexpression resulted in a protective effect against doxorubicin, but not other cytotoxic agents such as cisplatin, highlighting the selective role of the GST family in chemotherapeutic metabolism (65). It’s also important to recognize the ability for GST group members to regulate key cell survival pathways as well. One GST isoform, GSTP1-1, is capable of inhibiting the activity of c-Jun N-terminal kinase (JNK), thus disrupting the mitogen-activated protein kinase (MAPK) pathway. In doing so GSTP1-1 prevents cellular apoptosis, and improves tumor cell survival (66). It’s possible that through both its enzymatic and regulatory signaling activity, the GST family provides a dual mechanism for initiating MDR.

As discussed, one of the most studied and well described mechanisms associated with MDR is changes in the transport of chemotherapeutics. If these agents are not readily transported into the cytoplasm, or they are quickly removed, their ability to carry out their cytotoxic effects are severely restricted. While drug efflux has been shown to have the most significant effect on
MDR development, researchers are now looking at the role chemotherapeutic drug efflux might play in MDR. Most chemotherapeutic agents are transported into the cell through a group of influx transport proteins called the solute carriers (SLC) transport proteins. These proteins function through facilitated diffusion as both co-transporter and counter transporter proteins to allow for the cellular uptake of not only chemotherapeutic drugs, but many other important metabolites (67). SLC transporter dysfunction has been associated with certain disease conditions including inflammatory bowel disease and hyperbilirubinaemia (68). One specific member, SLC22A1, has been associated with doxorubicin influx across tissue types (69). Despite this, our understanding of their regulatory role in MDR requires further investigation.

1.8 H2S as a putative regulator of MDR

Given the high incidence rate and serious impact that MDR in HCC has on patient survival, the need to study new signaling mechanisms associated with the onset of MDR in these tissues is critical (14). The potential for MDR-related H2S signaling can be highlighted by one study that found an increase in the response of ovarian cancer cells (A2780) to the chemotherapeutic agent cisplatin, through the silencing of the H2S-generating gene CBS (24). These findings were shown to extend to in vivo mouse models of ovarian cancer, where CBS-directed siRNA coupled with cisplatin treatment had the most significant reduction in tumor size. In a similar manner, CSE and CBS inhibition increased the sensitivity of lung adenocarcinoma cells (A549) to another chemotherapeutic drug oxaliplatin (70). Other studies have noted increases in the levels of CSE and CBS in chemotherapeutic-resistance colon cancer cells (HCT116) compared to non-resistant cells (71). While these studies highlight the ability for H2S to induce MDR, the sometimes conflicting nature of H2S signaling presents the possibility for H2S to alternatively restrict MDR development, however this required further investigation. The
exceptionally high levels of H₂S production shown in the liver suggests a key importance within these tissues. Given the high levels of liver H₂S production, as well as the ability for H₂S to regulate the response of cancer cells to various chemotherapeutics, the role of H₂S in the regulation of MDR in HCC requires further investigation. Building upon these studies, this project looks to determine the possible involvement of H₂S signaling in MDR in HCC and the underlying mechanisms. Through the use of human HCC (HepG2) cell lines and doxorubicin as a model chemotherapeutic agent, this study aims to investigate: 1), the interaction of doxorubicin and H₂S on HepG2 cell viability and clonogenic formation; 2), the effect of doxorubicin on endogenous H₂S signaling; 3), the regulation of ABC transporters, GST, and/or SLC in H₂S-altered MDR and the possible underlying mechanisms. In doing so, we hope to discover the potential role for H₂S as a clinically relevant tool for the management of chemotherapeutic drug resistance in liver cancer.

2. Methods

2.1. Cell culture

HepG2 cells were obtained from American Type Culture Collection (Manassas, VA) and cultured with Dulbecco's modified Eagle's medium (Sigma-Aldrich, Oakville, ON) supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin at 37°C in a humidified atmosphere of 5% CO₂. The cells with 70-80% confluence were used for various treatments.
2.2. Establishment of a doxorubicin-resistant HepG2 cell line

A doxorubicin-resistant HepG2 cell line was established by continuous exposure to low dose doxorubicin for a period of over 2 months. HepG2 cells were treated with an initial dose of 50 nM doxorubicin for one month, followed by another month of 75 nM doxorubicin treatment. The medium was changed every 3 days. Doxorubicin-resistant HepG2 cells were determined based on morphological changes and a decreased sensitivity to doxorubicin treatment. Doxorubicin-resistant HepG2 cells were cultured in normal medium without doxorubicin for 1 week prior to various treatments.

2.3. Cell viability assay

The effect of doxorubicin and NaHS treatment on the cell viability was measured with MTT assay as previously described (72). Briefly, 20,000-40,000 cell/well were seeded into a 96 well plate in 200 µl of medium for 24 hours at 37°C. Cells were then washed with 100 µl PBS. After that, 200 µl of medium containing either doxorubicin and/or NaHS were added for an additional 24-hour incubation. Following the treatment, cells were again washed with 100 µl PBS, and 100 µl of MTT (1 mg/ml) was added to each well. Following a 4-hour incubation at 37°C, MTT was removed and 100 µl of DMSO was added for 10 minutes. Absorbance at 570 nM was read with a FLUOstar OPTIMA microplate spectrophotometer (BMG LABtech, Germany). Cell viability was expressed as a percentage of untreated control.
2.4. Clonogenic assay

To determine the effect of doxorubicin and H₂S treatments on the colony forming abilities of HepG2 cells, a clonogenic assay was performed as previously described with some minor changes (73). HepG2 cells were first treated with/without doxorubicin (1 μM) in the presence or absence of NaHS (30 μM) for 24 hours. After that, the cells were washed with 2 mL PBS and trypsinized for cell counting. A total of 15,000 cells were plated into 35 mm dishes containing 2 mL regular medium. The cells were cultured at 37 °C for 2 weeks with medium changed every 3 days. Following fixation with acetic acid/methanol (1:7) and staining with crystal violet (0.5%), the pictures of the plates were taken and colony numbers were analyzed using Image J 1.43 software.

2.5. Western blotting

After different treatments, the cells were collected and lysed in the presence of protease inhibitors. The resultant extracts were centrifuged at 15,000 rpm for 15 minutes at 4°C for protein separation. Equal amounts of proteins (60 μg) were mixed with loading buffer and placed at 95°C for 5 minutes, followed by separation with a 10% SDS-PAGE gel and transfer onto to nitrocellulose membranes (Pall Corporation, Pensacola, FL). The membranes were probed with appropriate primary antibodies and detected using peroxidase-conjugated secondary antibodies (Sigma-Aldrich, 1:5000) and visualized by ECL (GE Healthcare, Amersham, UK) (55). The following antibodies were diluted as follows with 3% milk in PBST: CSE 1/1000 (Protech, Rosemont, IL), CBS 1/100 (Santa Cruz, Dallas, TX), 3MST 1/1000 (Abnova, Walnut, CA), ABCA1 1/1000 (Abcam Toronto, ON), ABCB1 1/100 (Santa Cruz, Dallas, TX), ABCG8 1/100
(Santa Cruz, Dallas, TX), LXRα 1/1000 (Abcam, Toronto, ON), LXRβ 1/1000 (Cell Signaling Tech., Danvers, MA), and β-actin 1/5000 (Sigma-Aldrich).

2.6. Real-time PCR

Total RNA from the cells was collected using TriReagent (Sigma-Aldrich) and then reverse-transcribed into cDNA using random hexamer primers according to manufacturer’s protocol (Thermo Fisher Scientific, Ottawa, ON). Controls processed in the absence of reverse transcriptase were used to monitor contamination. The quantification of mRNA expression was performed with an iCycler iQ5 apparatus (Bio-Rad, Mississauga, ON) associated with the iCycler optical system software (version 3.1) using SYBR Green PCR Master Mix (Bio-Rad). The sequences of primers were: SLC22A16 (5’-CCTGGCGCCGTTCTCTGTGG-3’ and 5’-CTGGGGGTAAAAATGCTCAAGTTTTT-3’), GST (5’-AGGTTTTTGCCCAATCCAGAACAG-3’ and 5’-GTAGATCCGTGCTCCGACAAATA-3’), and GAPDH (5’-GCGGGGCTCTCCAGAACATCAT-3’ and 5’-CCAGCCCCAGCGTCAAAGGTG-3’). Relative mRNA quantification was calculated by using the arithmetic formula “2−ΔΔCT”, where ΔCT is the difference between the threshold cycle of a given target cDNA and an endogenous reference of GAPDH gene.

2.7. Measurement of H2S production rate

H2S production rate, reflecting CSE activity, was measured with a methyl blue method as commonly described (74). Briefly, 10% w/v mouse liver tissue homogenates were mixed with 100 mM potassium phosphate buffer, 10 mM L-cysteine, 2 mM pyridoxal 5’-phosphate, with or without 1 mM doxorubicin in the reaction flask. A center well containing 0.5 ml 1% zinc acetate
with a piece of filter paper (2 cm × 2.5 cm) was also put into the reaction flask. After being
flushed with N₂, the flask was kept at 37°C for 90 minutes. To stop the reaction, 0.5 ml of 50%
trichloroacetic acid was added to the flasks. The flasks were then incubated at 37°C for 60
minutes. After incubation, the contents of the center wells were then transferred to test tubes
containing 3.5 ml H₂O, and then 0.5 ml of 20 mM N,N-dimethyl-p-phenylenediamine sulfate in
7.2 M HCl and 0.5 ml of 30 mM FeCl₃ in 1.2 M HCl were added into the test tubes for 20
minutes. The methylene blue generated from the reaction was quantified at 670 nm using a
FLUOstar OPTIMA microplate spectrophotometer. The H₂S produced from each reaction was
determined with a standard curve of NaHS and expressed in nmole/g/min.

2.8. H₂S direct interaction

The direct interaction of doxorubicin with H₂S was analyzed with a lead sulfur method to
determine the ability for doxorubicin to sequester free H₂S in solution (75). Briefly, 100 µl of
solution containing 30 µM NaHS with or without 1 µM doxorubicin was placed in a 96-well
plate. Lead acetate paper was placed above the liquid phase contained in the 96-well plate with a
cover. The reaction was incubated for 1 hour at 37°C in the dark. The well only containing NaHS
acted as control. The lead acetate paper was then scanned and analyzed with Image J software.

2.9. Doxorubicin efflux and influx assay

After HepG2 cells were treated with doxorubicin and/or NaHS for 24 hours, the cells were
washed twice with PBS, and incubated with 2 mL PBS for additional 2 hours. Afterward, 1 mL
sample of PBS was first taken from each plate for measurement of doxorubicin efflux. The cells
were then collected for analysis of doxorubicin influx. The fluorescence of doxorubicin was read
at an excitation wavelength of 485 nm and an emission wavelength of 590 nm using a FLUOstar OPTIMA reader as previously described (76). The images of doxorubicin fluorescence were also taken using an inverted Olympus IX70 fluorescence microscope.

2.10. S-sulfhydration assay

LXR\textalpha\ S-sulfhydration was performed as described previously (26, 77, 78). Briefly, cells were sonicated in buffer containing 250 mM Hepes buffer (pH 7.7), 1 mM EDTA, 0.1 mM neocuproine and 100 µM deferoxamine following centrifuge at 13,000 × g for 30 min at 4°C. Cell lysates were added to blocking buffer (sonication buffer with 2.5% SDS and 20 mM MMTS) at 50°C for 20 min with frequent mixing using vortex. The proteins were precipitated with acetone at -20°C for 20 min, then the proteins were resuspended in blocking buffer (with 1% SDS) following addition of 4 mM biotin-HPDP. After incubation for 3 hours at 25°C, biotinylated proteins were precipitated by streptavidin-agarose beads, which were then washed with blocking buffer. The biotinylated proteins were eluted by SDS-PAGE gel and subjected to Western blotting analysis using anti-LXR\textalpha\ antibody.

2.11. Statistical Analysis

The data were presented as means ± SEM, representing at least 3 independent experiments. Statistical comparisons were made using two-tailed Student's \( t \)-tests or one-way ANOVA followed by a post-hoc analysis (Tukey test) where applicable. Values of \( p<0.05 \) were considered to be statistically significant.
3. Results

3.1 The effects of doxorubicin and H₂S treatment on HepG2 cell survival

First, the effect of doxorubicin on HepG2 cell viability was evaluated with an MTT assay. We observed that cell viability was decreased in a dose-dependent manner when the cells were exposed to increasing concentrations of doxorubicin for 24 hours (Fig. 4A). Doxorubicin at 1 µM decreased cell viability by 35.2%, while cell viability was only 28.2% in 10 µM doxorubicin-incubated cells in comparison with the control cells (100%). We next incubated HepG2 cells with NaHS, a well-known H₂S-releasing donor (79). The result demonstrated that cell viability was not affected by exogenously applied NaHS (1-100 µM) (Fig. 4B). To further study the interaction of doxorubicin and H₂S on cell viability, HepG2 cells were co-cultured with varying concentration of doxorubicin (0.1-10 µM) and NaHS (30 µM) for 24 hours. The growth inhibitory effects of doxorubicin/NaHS combination were significantly higher than those caused by doxorubicin alone (Fig. 4C). The cell viability in the treatment with both doxorubicin (1 µM) and NaHS (30 µM) was only 38.5% when compared with that (62.8%, p<0.05) in the treatment with doxorubicin (1 µM) alone. As shown in Fig. 4D, doxorubicin at 1 µM treatment significantly reduced HepG2 cell confluence, which was exaggerated by co-treatment with 30 µM NaHS over 24 hours.
Figure 4. H$_2$S sensitizes HepG2 cells to doxorubicin cytotoxicity. (A) Doxorubicin dose-dependently decreased cell viability. HepG2 cells were incubated with doxorubicin at the indicated concentration (0.03-10 µM) for 24 hours. After that, cell viability was measured by MTT assay. #, p<0.05 versus control. (B) NaHS had no effect on cell viability. HepG2 cells were incubated with NaHS (1-100 µM) for 24 hours. After that, cell viability was measured by MTT assay. (C) NaHS enhanced the sensitivity of HepG2 cells to doxorubicin cytotoxicity. HepG2 cells were co-cultured with varying concentration of doxorubicin (0.1-10 µM) and NaHS (30 µM) for 24 hours. After that, cell viability was detected by MTT assay. *, p<0.05 versus the group with doxorubicin alone. (D) Morphology and confluence changes in HepG2 cells after treated with doxorubicin (1 µM) and/or NaHS (30 µM) for 24 hours. Scale bar: 20 µm. The data were from at least 3 independent experiments.
3.2 H$_2$S and doxorubicin-induced changes in the clonogenic formation of HepG2 cells

An important hallmark of cancerous cells is the ability to quickly form large colonies, ultimately resulting in a tumorous mass. A clonogenic assay was then performed to quantify the effects of H$_2$S and doxorubicin on the colony forming ability of HepG2 cells (73). HepG2 cells were treated 1 μM doxorubicin and/or 30 μM NaHS for 24 hours. The treated cells were then split to new plates at equal cell numbers and cultured for 2 weeks. The resultant colonies were visualized using crystal violet and quantified using image J software (Fig 5A). Co-treatment with both doxorubicin and H$_2$S significantly inhibited colony formation to a greater degree than doxorubicin treatment alone, while NaHS treatment did not have a statistically significant effect (Fig 5B).
Figure 5. H₂S sensitizes HepG2 cells to colony disruption by doxorubicin treatment.

Following 24-hour treatments with 1 µM doxorubicin and/or 30 µM NaHS for 24 hours, the cells were split into fresh plates and re-cultured for 2 weeks. Colony formation was visualized using crystal violet staining (A) and number of colonies were quantified using image J software analysis (B). *, p<0.05 versus control; #, p<0.05 versus doxorubicin alone. The data were from 3 independent experiments.
3.3 The effects of doxorubicin on H2S-generating enzymes in HepG2 cells

We next determined the effect of doxorubicin on the protein expressions of 3 H2S-generating enzymes. As observed in Fig. 6A, CSE protein expression was significantly decreased when HepG2 cells were treated with 1 μM doxorubicin for 24 hours, while CBS expression was not affected by doxorubicin. The protein expression of 3MST was not detectable in HepG2 cells. CSE is a major H2S-generating enzyme in liver tissues (14). We then measured the effect of doxorubicin on endogenous H2S generation from mouse liver tissues with a methyl blue method. Fig. 6B showed that doxorubicin significantly decreased H2S production by 80%, indicating that doxorubicin may also directly block CSE enzymatic activity. To further investigate the possibility of direct interaction between doxorubicin and H2S, doxorubicin at 1 μM was mixed with 30 μM NaHS, which was then exposed to lead acetate paper at 37°C for 1 hour. As shown in Fig. 6C, it seems that there was no direct chemical reaction between doxorubicin and H2S.
Figure 6. Doxorubicin attenuates H₂S production in HepG2 cells. (A) Doxorubicin inhibited the protein expression of CSE but not CBS. After HepG2 cells were treated with 1 µM doxorubicin for 24 hours, the protein expressions were detected by western blotting. *, p<0.05 versus control. (B) Doxorubicin reduced endogenous H₂S production. Mouse liver tissues were processed for H₂S measurement by methyl blue method in the presence of 1 µM doxorubicin. *, p<0.05. (C) Doxorubicin did not react with H₂S. Doxorubicin (1 µM) and NaHS (30 µM) were mixed together followed by detection of H₂S release by acetate lead paper at 37°C for 1 hour. *, p<0.05. The data were from at least four independent experiments.
3.4. H$_2$S modulates doxorubicin trafficking in HepG2 cells

To understand the mechanism underlying the synergistic effect of doxorubicin and H$_2$S combination treatment, the efflux and influx of doxorubicin in HepG2 cells were measured with a fluorescence plate reader. We found that exogenously applied H$_2$S inhibited the efflux of doxorubicin by 80% in comparison with doxorubicin treatment alone (Fig. 7A). As expected, intracellular doxorubicin concentration was increased significantly upon doxorubicin and NaHS combination treatment compared to that observed with doxorubicin alone (Fig. 7B). The differences of fluorescence intensity between doxorubicin alone and doxorubicin/H$_2$S co-treatment were further validated with a fluorescent microscopy (Fig 7C)
Figure 7. H$_2$S promotes cellular retention of doxorubicin in HepG2 cells. H$_2$S inhibited efflux of doxorubicin (A) but enhanced cellular retention of doxorubicin (B). Twenty-four hours after HepG2 cells were treated with doxorubicin and/or NaHS, the cells were washed and incubated with 2 mL PBS for additional 2 hours. Afterward, 1 mL sample of PBS was first taken for measurement of doxorubicin efflux (A). The cells were then collected for analysis of doxorubicin influx (B). Fluorescence intensity was normalized to equal amount of proteins loaded, and the intensity in doxorubicin treated group was expressed as 100%. *, p<0.05. The images of cellular doxorubicin internalization were captured using fluorescence inverted microscopy (C). Scale bar: 20 µm. The data were from at least three independent experiments.
3.5 Effects of doxorubicin and H₂S on the expression of ABC transport proteins in HepG2 cells.

ABC transport proteins are responsible for the efflux of doxorubicin in many cell types (59). We next assessed the effect of both doxorubicin and H₂S on the protein expression of several ABC transporters, including ABCA1, ABCB1 and ABCG8, which have been demonstrated to be highly expressed in HCC. In comparison with the control cells, incubation of HepG2 cells with 1 μM doxorubicin for 24 hours increased the protein expressions of ABCA1 and ABCG8 by 2.1 fold and 1.8 fold respectively (Fig. 8). The stimulatory effect of doxorubicin on ABCA1 and ABCG8 expressions was markedly reversed by exogenously applied H₂S. In contrast, the protein expression of ABCB1 was not affected by either doxorubicin or H₂S. These results suggest that the inhibition of ABCA1 and ABCG8 by H₂S resulting in the increased accumulation of intracellular doxorubicin, is a potential mechanism underlying the synergistic effects of doxorubicin and H₂S on cancer cell death.

Figure 8. H₂S reverses doxorubicin-induced expression of ABCA1 and ABCG8 but not ABCB1. HepG2 cells were treated with doxorubicin alone (1 μM) and/or NaHS (30 μM) for 24 hours. The protein expressions of ABCA1, ABCG8, and ABCB1 were analyzed with western blotting. *, p<0.05 versus all other groups. The data were from four independent experiments.
3.6 The effect of doxorubicin and H_{2}S on LXR\(\alpha\) expression and S-sulfhydration

We further investigated the signalling pathways associated with altered expression of ABCA1 and ABCG8 by doxorubicin and H_{2}S. The LXR group is a family of transcriptional regulatory proteins that have been associated with the regulation of ABC gene expression (60). Western blotting was further conducted to analyze the expressions of both LXR\(\alpha\) and LXR\(\beta\) in HepG2 cells. No change in the expression of LXR\(\alpha\) was seen with doxorubicin and/or H_{2}S treatment (Fig. 9), while LXR\(\beta\) was not detectable in this cell type. We then asked whether H_{2}S can post-translationally modify LXR\(\alpha\) via S-sulfhydration leading to altered trans-activation activity. With a biotin switch assay, we did not detect LXR\(\alpha\) S-sulfhydration after the cells were treated with doxorubicin (1 \(\mu\)M) and/or H_{2}S (30 \(\mu\)M) for 24 hours (data not shown). These data exclude the possibility of LXR\(\alpha/\beta\) in mediating the altered expressions of ABCA1 and ABCG8 by doxorubicin and H_{2}S.

![Figure 9. LXR\(\alpha\) is not altered by doxorubicin and/or H_{2}S.](image)

HepG2 cells were treated for 24 hours with doxorubicin (1 \(\mu\)M) and/or NaHS (30 \(\mu\)M). The protein expressions of LXR\(\alpha\) and LXR\(\beta\) were then analyzed by western blotting. The experiments were repeated for 3 times.
3.7 Doxorubicin and H₂S regulate GST and SLC22A1 expression in HepG2 cells

To further explore other mechanisms for the increased retention of doxorubicin by H₂S, the mRNA expression level of GST and SLC22A1 were determined by real-time PCR. GST is capable of detoxifying doxorubicin through catalyzing it’s conjugation with glutathione (62), while SLC22A1 has been proposed as a potential doxorubicin influx transport protein (67). Doxorubicin slightly induced the mRNA expression of GST, but it did not reach significance. In addition, NaHS alone or doxorubicin and NaHS combination significantly induced GST mRNA expression (Fig. 10). More interestingly, doxorubicin and NaHS combination treatment stimulated the mRNA expression of SLC22A1 by 160% when compared with the control cells. Either doxorubicin or NaHS alone had no significant effect on SLC22A1 expression.
Figure 10. Effect of doxorubicin and H₂S on the mRNA expression of GST and SLC22A1.

HepG2 cells were treated for 24 hours with doxorubicin (1 μM) and/or NaHS (30 μM). The cells were then collected for real-time PCR analysis of GST and SLC22A1 mRNA expressions. *, p<0.05 versus control. The data were from four independent experiments.
3.8. Characterization of doxorubicin drug resistance in HepG2 cells

To further elucidate the functional significance of H₂S in drug resistance in HCC, we established an *in vitro* model of doxorubicin-resistant HepG2 cells (D.R. HepG2) by long term treatment of HepG2 cells with low dose of doxorubicin (80). In comparison with the parental (W.T.) HepG2 cells, D.R.-HepG2 cells were flatter with an enlarged cytoplasm (Fig. 11A). We further observed that CSE expression was quite lower in D.R. HepG2 in comparison with the W.T. HepG2 cells (Fig. 11B). Next, we compared the sensitivity of both cell types to doxorubicin and H₂S. After seeding equal numbers of both cell types in new plates, D.R. HepG2 grew faster (122%) than the parental W.T. HepG2 cells (100%) in the normal culture medium. Doxorubicin at 1 μM decreased HepG2 cell viability by 61.5% but only 12.3% in D.R. HepG2 cells, suggesting that D.R. HepG2 cells are resistant to doxorubicin-arrested cell growth. NaHS at 30 μM had no effect on the cell viability of parental W.T. HepG2 cells but significantly decreased the viability of D.R. HepG2 cells. The addition of NaHS restored the sensitivity of D.R. HepG2 cells to doxorubicin-induced cell growth inhibition (Fig. 11C).
Figure 11. H$_2$S sensitizes drug resistant D.R. HepG2 cells to doxorubicin treatment. (A) D.R. HepG2 cells were flatter with an enlarged cytoplasm. D.R. HepG2 cells were obtained by continuous exposure to low dose doxorubicin (50-75 nM) for a period of over 2 months. (B) CSE expression was lower in D.R. HepG2 cells. Both parental W.T. HepG2 cells and W.T. HepG2 cells were cultured in normal medium without doxorubicin for 1 week prior to detection of CSE expression by western blotting. (C) H$_2$S sensitized D.R. HepG2 cells to doxorubicin treatment. Equal number of parental W.T. HepG2 cells and D.R. HepG2 cells were seeded in 96-well plate for 1 days followed by treatment with doxorubicin (1 μM) and/or NaHS (30 μM) for 24 hours. After that, cell viability was analyzed by MTT assay. *, p<0.05 versus parental W.T. control; #, p<0.05 versus parental W.T. cells with doxorubicin treatment; &, p<0.05 versus D.R. HepG2 cells with no treatment or doxorubicin treatment. The experiments were repeated for at least 3 times.
4. Discussion

One of the major limitations in the chemotherapeutic treatment of cancer is the development of MDR. In HCC, MDR is characterized by changes in drug transport, metabolism, and its ability to alter intracellular targets. Given the unique and critical role of H₂S in various cellular functions, the ability of H₂S to regulate the development of MDR in HCC deserves further investigation (81).

The chemotherapeutic agent doxorubicin has been well described as having strong anti-proliferative effects in cancer lines including HepG2. Doxorubicin induces cell death through the direct intercalation with DNA and disruption of topoisomerase II, as well as through the production of ROS. ROS themselves can induce oxidative damage to cellular membranes, DNA, and proteins, due to the reactivity of the oxygen free radicals (82). Our studies here validated that doxorubicin reduces HepG2 cell viability in a dose-dependent manner, and H₂S supplementation (30 μM) sensitizes the cells to doxorubicin cytotoxicity, while H₂S treatment alone has no effect on cell viability. These results were further confirmed by the studies with colony formation. Consistent with the cell viability data, exogenously applied H₂S strengthens the ability of doxorubicin to disrupt HepG2 colony formation, while H₂S alone has no effect on colony formation. A 30 μM NaHS treatment was selected because, upon dissociation, this chemical would supply an H₂S dosage in the low μM range, most closely reflecting endogenous H₂S production levels (14). Also, the rapid release of H₂S from NaHS treatments allowed for effective co-treatment timing with doxorubicin (79).
To further investigate the mechanism associated with these changes in doxorubicin cytotoxicity, the expression of a group of membrane-bound efflux transport proteins known as the ABC transport proteins was studied. Of the members of the ABC group, ABCB1 is the most well described in MDR development for its ability to facilitate the efflux of chemotherapeutic agents including doxorubicin, and thus reduce their cytotoxicity (83). ABCA1 and ABCG8 were also selected for analysis because of their high levels of expression in the liver, their role in hepatic efflux transport, as well as the lack of research investigating their role in MDR development (51, 84). Current understanding on the role of ABCA1 focuses on it’s importance as a cholesterol efflux transporter expressed highly in the liver (84), however some evidence has shown an ability for it to regulate chemotherapeutic cytotoxicity in lung cancer cells (58). Likewise, there has been little insight on the role of ABCG8 in MDR development, however ABCG2/BCRP, a member of the same sub-group, has been well described as an MDR protein in breast cancer cells (57). We have shown that in doxorubicin (1 μM) treated HepG2 cells, the expression of both ABCA1 and ABCG8 is increased, and that H2S supplementation (30 μM) returns the expression level of these proteins back to a control state, while the expression of ABCB1 was shown to not be affected by any of the treatments. H2S treatment (30 μM) alone did not affect the expression of any of the proteins. Overexpression of ABC transport proteins is one of the most well described mechanisms for the onset of MDR, as the increased number of efflux transporters reduces the ability for chemotherapeutics to accumulate in the cancerous cells and carry out their cytotoxic functions (85). The ability for H2S treatments to restrict the expression of these proteins could explain the increase in doxorubicin/H2S co-treatment cytotoxicity seen in the cell viability studies. To determine if doxorubicin/H2S-induced changes in ABCA1 and ABCG8 levels correspond to changes in doxorubicin transport, a doxorubicin fluorescence assay
was performed in HepG2 cells. Using doxorubicin’s intrinsic fluorescent qualities, the intra/extracellular localization of doxorubicin could be tracked (76). These results show that co-treatment of doxorubicin (1 μM) with H2S (30 μM) increases the intracellular fluorescence, and therefore doxorubicin content, of HepG2 cells. Some studies have suggested that intracellular doxorubicin fluorescence may not be reflective of intracellular toxicity, as inactivated doxorubicin can still fluoresce (86). However, the doxorubicin/H2S cell viability studies can confirm that an H2S-induced increase in doxorubicin accumulation causes increased cytotoxicity and thus HepG2 cell death. Our findings therefore suggest an expanded role for ABCA1 and ABCG8 in HCC cells, as efflux transporters of chemotherapeutic agents, specifically doxorubicin. The importance of ABCB1 in MDR has been well established in several different cancer lines including HepG2, however, our results suggested otherwise (87, 88). It is important to note that previous studies have conducted their experiments with established doxorubicin resistant cell lines, without studying the effects of initial doxorubicin treatment in wild-type cells. As such, their results may reflect the exaggerated changes in ABC transport protein expression seen in already resistant cell lines. Our findings may instead reflect more sensitive changes seen in the initial establishment of doxorubicin resistance in wild-type cells, offering novel insight into the importance of other ABC transporters previously not studied.

The Liver X Receptor (LXR) group is a family of nuclear receptors that are important regulators of cholesterol metabolism. The two subgroups, LXRα and LXRβ, differ only in tissue distribution, with LXRα predominately in the liver, and LXRβ found in most tissues. The importance of both LXR groups in the regulation of cholesterol metabolism makes them key regulators of certain ABC-transport protein expression (89). In one study, it was shown that the
hepatic expression of ABCG8 and ABCA1 is greatly reduced by the inhibition of LXRα and β (60). In a separate study, the use of LXR agonists had no effect on the regulation of ABCB1 in HepG2 cells (90). Taken together, these findings suggest that H2S is capable of regulating specifically ABCA1 and ABCG8, but not ABCB1, through the targeting of LXR’s in HepG2 cells. In order to study this, HepG2 cells were treated with doxorubicin (1 μM) with or without NaHS (30 μM) and NaHS (30 μM alone). We found no effect of any treatment group on the expression of LXRα, while LXRβ was not expressed at measurable levels. Given these results, it is unlikely that H2S modulates the expression of LXRα to exert its regulatory effects over ABCA1 and ABCG8. We next wanted to investigate the ability of H2S to instead regulate the activity of LXRα through protein S-sulfhydration. Through the addition of sulfur groups to the cysteine residues of target proteins, H2S is capable of inducing changes in the structure and thus the function of proteins (5). Again, it was shown that H2S treatment had no measurable effect on the level of LXRα sulfhydration, allowing us to conclude that the LXR group is unlikely the intermediate signaling complex through which H2S exerts its effects on ABCA1 and ABCG8.

Our future studies will look to investigate other possible regulatory elements through which H2S regulates ABC protein expression. One possible candidate for this role is the retinoid X receptor (RXR) group, a family of nuclear receptors expressed highly in the liver and associated with regulation of cholesterol metabolism through the formation of heterodimers with LXRα/β (91). Studies have shown the ability for RXR activation to induce the expression of ABCA and ABCG subgroup members, pointing to the possibility of RXR as the intermediate signaling complex between H2S and ABCA1/G8 (92).
While efflux transport is the best described mechanism associated with MDR, the pathways associated with influx transport and metabolism may offer new research avenues for the prevention of this condition in HCC. The role of the SLC transporter group of proteins is just now becoming recognized for its potential role in the influx transport of various chemotherapeutics, including doxorubicin (93). The SLC group is responsible for regulating metabolite and ion influx but has also shown the ability to regulate chemotherapeutic influx as well, specifically in the SLC22 subfamily. SLC22A1-transfected colon cancer cells showed a significant increase in the accumulation of oxaliplatin, a derivative of cisplatin, improving the cytotoxicity of the drug. Further studies showed differential mRNA expression of SLC22A1 in various colon cancer tumors, suggesting tissue specific variations in the degree of chemotherapeutic effectiveness (94). In order to describe the role of SLC22A1 in the regulation of doxorubicin management in HepG2 cells, we treated the cells with doxorubicin (1 µM) with or without NaHS (30 µM) and NaHS (30 µM alone) (Fig 10). The findings showed that doxorubicin treatment alone had no effect on the levels of SLC22A1 mRNA in Hep-G2 cells, and thus is unlikely to be associated with the onset of MDR in this cell line. Co-treatment with both doxorubicin and H$_2$S showed an increase in SLC22A1 mRNA expression, however H$_2$S treatment alone had no significant effect. Both doxorubicin alone and H$_2$S alone treatments showed an increasing trend, and despite not being enough to qualify for statistical significance, could describe the synergistic effect that combined treatment had. As such, it is plausible that both doxorubicin and H$_2$S treatment function to improve doxorubicin intracellular accumulation, however in a pathway distinct from that regulating ABC transport proteins. The likelihood for distinct regulatory mechanisms controlling both chemotherapeutic influx and efflux offers both daunting and exciting research possibilities.
The metabolism of chemotherapeutic agents is another mechanism in which drug resistance can be established. The GST family is a large group of enzymes capable of processing toxic chemical agents for removal from the body. Elevated levels of GST across various cell lines has been associated with the development of MDR, and thus may be associated with similar regulation in HepG2 cells (95, 96). In the present study, doxorubicin treatment alone had no effect on the levels of GST expression, however we saw an increasing trend, suggesting that longer, or higher dose treatments perhaps could exaggerate these effects. Combined treatment of doxorubicin and NaHS showed a significant increase in GST mRNA, indicating a synergistic effect similar to that seen in the regulation of SLC22A1. H2S alone also significantly increased GST expression in these cells. These findings taken alone may indicate that H2S actually perpetuates MDR through the up regulation of GST, but given our cell viability findings and the cellular level effects of H2S on doxorubicin toxicity, this is unlikely to be the case. While studies have shown that H2S up regulates GST levels in various cell lines (97, 98), our cell viability and clonogenic studies suggest that the sum of the effects of H2S on doxorubicin cytotoxicity in HepG2 cells is an increased sensitivity to the drug.

We also tested the effect of doxorubicin on endogenous H2S signaling in HepG2 cells. The protein levels of all 3 of the H2S-generating enzymes, including CSE, CBS and 3-MST, were compared following doxorubicin treatment (1 μM). Our findings demonstrated that only CSE but not CBS was down-regulated by doxorubicin. The protein expression of 3-MST was not detected. It has been observed that CSE is highly expressed in liver tissues, and knockout of CSE diminishes most H2S production in mouse liver tissues, supporting our findings (14). We also
measured the effect of doxorubicin on H$_2$S production rate in mouse liver tissues and found that
doxorubicin significantly reduced the production rate of H$_2$S in these tissues. These same effects
were also reported in rat cardiac (H9C2) cells (99) following 24 hour doxorubicin (5 µM)
treatment. Together, these findings strongly suggest that doxorubicin is capable of inhibiting
CSE expression, and therefore endogenous H$_2$S production in HepG2 cells, possibly through its
strong DNA intercalation properties, however this requires further investigation (100). When
considered with the data of cell viability, doxorubicin transport, and ABC protein expression
data, it seems that this loss of H$_2$S production ultimately leads to pro-MDR related signaling
events in HepG2 cells.

We have also established a doxorubicin resistant (75 nM) HepG2 cell line in order to
study changes in H$_2$S signaling and doxorubicin sensitivity, and to compare these characteristics
with wild-type HepG2 cells. Morphological features of the D.R. cell line included an irregular
shape and enlarged cytoplasm, characteristics similar to those of doxorubicin resistant breast
cancer cells (101). Some studies have focused on the importance of epithelial-mesenchymal
transition (EMT) in the morphological changes associated with MDR cells. EMT is a process in
which cancerous cells undergo cytoskeletal rearrangement to improve their migratory ability
(102). In various cancer cell lines, increased activity of the EMT pathway has been associated
with not only metastasis, but also the onset of MDR. Resistant cells often exhibit EMT
phenotype changes including increases in cell size and irregular cell structure (103). The role of
EMT in HepG2 MDR development has yet to be studied but could present an important avenue
of future research. Upon establishment of a D.R. HepG2 cell line, experiments were performed
to determine changes in doxorubicin sensitivity and H$_2$S production between W.T. and D.R. cell
lines. Non-treated D.R. HepG2 cells exhibited a significant decrease in CSE expression compared to W.T. cells, similar to that seen in doxorubicin treated W.T. cells. The ability for D.R. alone to induce CSE down-regulation without direct doxorubicin treatment suggests that it may not be the doxorubicin itself effecting CSE expression, but instead doing so through an indirect signaling mechanism, however this requires further investigation. Decreased H_2S producing enzyme levels in D.R. but not W.T. cells, once again implicates the importance of endogenous H_2S in regulating doxorubicin transport. In order to study the effects of D.R. resistance on doxorubicin/H_2S induced cell death, cell viability analysis was performed on both W.T. and D.R. Hep-G2 cells. The statistically significant decrease seen in the viability of doxorubicin treated W.T. cells, but not in the doxorubicin D.R. cells, confirmed doxorubicin treatment was no longer an effective inhibitor of cell growth, and thus further confirmed this group as a doxorubicin resistant cell line. When exogenous H_2S was combined with doxorubicin treatment, both the W.T. and D.R. groups saw a very similar decrease in cell viability, greater than with doxorubicin alone. This further confirmed that H_2S is capable of sensitizing HepG2 cells to doxorubicin treatment, and in D.R. cells, actually returns their sensitivity back to a WT state. Applied in a clinical context, H_2S therefore could be used in conjugation with doxorubicin to not only improve initial doxorubicin treatment, but also to restrict the onset of MDR in HCC tissues. Recent studies have investigated doxorubicin/H_2S co-treatment in prostate and bone cancers and have even synthesized H_2S-releasing doxorubicin compounds. These compounds have shown an increased ability both in-vitro and in-vivo to reduce tumor size and induce cellular apoptosis through supplementation of doxorubicin with simultaneous H_2S release (104, 105).
5. Conclusions and future studies

These findings have shown that doxorubicin treatment is capable of decreasing CSE expression in HepG2 cells, and that exogenous H$_2$S is capable of sensitizing HepG2 cells to doxorubicin treatment, possibly by suppressing doxorubicin transporters, ABCA1 and ABCG8. These effects are not mediated by the interaction between H$_2$S and LXR family members, but perhaps through other related signaling complexes such as the RXR group, since RXR’s regulate the transcription of ABC transporters by interaction with LXR. In addition, we discovered that H$_2$S is capable of returning the sensitivity of doxorubicin resistant Hep-G2 cells to a non-resistant level. The ability for H$_2$S to sensitize HepG2 cells to doxorubicin treatment offers the possibility for improving the management of HCC through the use of chemotherapeutic agents. H$_2$S supplementation with doxorubicin may improve both the initial response of HCC treatment, as well as offer the ability to return D.R. HCC cells to a non-resistant state. The discovery of ABCA1 and ABCG8 as important transporters of doxorubicin in HepG2 cells, and the ability for H$_2$S to regulate their expression improves not only our understanding of the mechanisms associated with MDR development, but also the role of H$_2$S in liver physiology as whole. We hope that these novel regulatory functions of H$_2$S in the liver will be the basis for improving current HCC treatment methods, and will contribute to the development of H$_2$S as a clinically relevant tool. Building upon these findings, future studies will look to determine; A) how doxorubicin alters CSE expression in both W.T. and D.R. HepG2 cells; B) the mechanism in which H$_2$S affects ABCA1 and ABCG8 expression if not through LXR$\alpha$/\$\beta$; C) exploring the role of doxorubicin/H$_2$S on tumor growth in-vivo, through the use of xenograft animal models with W.T. vs D.R. induced HCC tumors; D) synthesizing novel H$_2$S-releasing doxorubicin
compounds capable of effectively targeting HCC tissues to improve current HCC treatment tools and strategies.
6. References


April 2018).


http://www.tandfonline.com/doi/abs/10.1080/15287399409531852 (13 April 2018).


https://www.nature.com/articles/s41389-017-0025-3.pdf?origin=ppub (15 April 2018).


chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations.


